Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback